Navigation Links
Bion Announces Approval of New Canadian Patent
Date:8/6/2012

NEW YORK, Aug. 6, 2012 /PRNewswire/ -- Bion Environmental Technologies, Inc. (OTC BB/QB: BNET) announced today that it was notified that its Canadian patent application 2503166 entitled "Low Oxygen Biologically Mediated Nutrient Removal" has been approved.  The patent application was made on April 18, 2005; upon publication and issuance, the patent will be officially granted and will remain in force until April 18, 2024.

The new patent provides protection of the core Bion process's ability to convert and remove both nitrogen and phosphorous from the effluent stream.  The patent describes the removal of both nitrogen and phosphorus similar to the United States patents in hand. 

James Morris, Ph.D., P. E., Bion's Chief Technology Officer, stated, "Canada represents a large potential market and this patent assures Bion's ability to deploy our technology in this important agricultural powerhouse."

The Canadian patent substantially strengthens the Company's international IP portfolio, with active patents now held in Canada, New Zealand and Mexico, and additional applications under consideration for the European Union, Brazil, Argentina and Australia. Bion holds seven US patents, with one pending.

Bion Environmental Technologies has provided environmental treatment solutions to the agriculture and livestock industry since 1990. Bion's patents protect its proprietary technology that uses a biological nutrient removal process driven by the system's active microbial community that utilize and metabolize the waste stream to convert potential pollutants to benign forms that can then be removed from the effluent discharge stream and converted into energy or other valuable by-products.  Bion systems provide effective environmental treatment at a substantially lower cost than conventional wastewater treatment plants that rely on expensive highly-oxygenated and chemical processes. 

Bion's environmental management system is the only technology able to provide a comprehensive solution to concentrated livestock waste, through simultaneous removal and stabilization of nutrients and reduction of air emissions including ammonia, hydrogen sulfide, VOC's, greenhouse gases, odors and other pollutants, together with reductions of pathogens, antibiotics and hormones in the discharge stream.  Bion's system can be configured to simultaneously reclaim renewable energy from the 'waste' biomass in a highly efficient process.  For more information, see Bion's websites, www.biontech.com and www.bionpa.com

This material includes forward-looking statements based on management's current reasonable business expectations. In this document, the words 'expect', 'will', 'proposed' and similar expressions identify certain forward-looking statements. These statements are made in reliance on the Private Securities Litigation Reform Act, Section 27A of the Securities act of 1933, as amended. There are numerous risks and uncertainties that could result in actual results differing materially from expected outcomes.


'/>"/>
SOURCE Bion Environmental Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... As Outsourcing of Cell Line Development Services Drives the ... by Expanding their Service Portfolio and Collaborating with Biopharmaceutical ... cell banking market addresses market sizing, emerging trends, and ... in the market. The base year considered is 2015 ... The cell banking market is expected to grow ...
(Date:1/24/2017)... ORANGE COUNTY, Calif. , Jan. 24, 2017 ... respiratory testing solutions, announced today that in ... providing advanced respiratory assessment to the Roche FIREFISH ... muscular atrophy (SMA) develop respiratory insufficiency due to ... alpha motor neurons in the spinal cord. This ...
(Date:1/24/2017)... Reha Technology USA Inc. has ... . The need for Robotic technology in the rehab space ... in the surgical space. Project Walk – Boston ... and adding technology to their continuum of care. They now have ... repetitions which has been shown to improve gait with patients. The ...
(Date:1/24/2017)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... nervous system (CNS) diseases, is pleased to announce that ... with the U.S. Food and Drug Administration (FDA), a ... LevoCap ER (REL-1015, levorphanol extended release, abuse deterrent capsules) ... filing is achievable.   "The FDA,s input ...
Breaking Biology Technology:
(Date:12/15/2016)...  There is much more to innovative access systems ... Continental will demonstrate the intelligence of today,s solutions at ... Through the combination of the keyless entry and start ... the international technology company is opening up new possibilities ... "The integration of biometric elements brings our expertise ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... Dec. 8, 2016  Singulex, Inc., the leader in ... entered into a license and supply agreement with Thermo ... agreement provides Singulex access to Thermo Scientific BRAHMS PCT ... is used to diagnose systemic bacterial infection and ... to aid in assessing the risk of critically ...
Breaking Biology News(10 mins):